Cabotegravir

Last updated

Cabotegravir
Cabotegravir (GSK744).svg
Cabotegravir ball-and-stick model.png
Clinical data
Trade names Vocabria, Apretude
Other namesS/GSK1265744, GSK744
AHFS/Drugs.com Monograph
MedlinePlus a621010
License data
Pregnancy
category
Routes of
administration 		By mouth, intramuscular
ATC code
Legal status
Legal status
Pharmacokinetic data
Protein binding >99%
Metabolism UGT1A1
Metabolites glucuronide
Elimination half-life tablets: 41 hours
injection: 5.6–11.5 weeks
Excretion 47% via feces, 27% via urine
Identifiers
  • N-((2,4-Difluorophenyl)methyl)-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro(1,3)oxazolo(3,2-a)pyrido(1,2-d)pyrazine-8-carboxamide
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard 100.306.452 OOjs UI icon edit-ltr-progressive.svg
Chemical and physical data
Formula C19H17F2N3O5
Molar mass 405.358 g·mol−1
3D model (JSmol)
  • C[C@H]1CO[C@H]2N1C(=O)c3c(c(=O)c(cn3C2)C(=O)NCc4ccc(cc4F)F)O

  • as salt: [Na+].C[C@H]1CO[C@@H]2CN3C=C(C(=O)NCC4=CC=C(F)C=C4F)C(=O)C([O-])=C3C(=O)N12
  • InChI=1S/C19H17F2N3O5/c1-9-8-29-14-7-23-6-12(16(25)17(26)15(23)19(28)24(9)14)18(27)22-5-10-2-3-11(20)4-13(10)21/h2-4,6,9,14,26H,5,7-8H2,1H3,(H,22,27)/t9-,14+/m0/s1
  • Key:WCWSTNLSLKSJPK-LKFCYVNXSA-N

  • as salt: InChI=1S/C19H17F2N3O5.Na/c1-9-8-29-14-7-23-6-12(16(25)17(26)15(23)19(28)24(9)14)18(27)22-5-10-2-3-11(20)4-13(10)21;/h2-4,6,9,14,26H,5,7-8H2,1H3,(H,22,27);/q;+1/p-1/t9-,14+;/m0./s1
  • Key:AEZBWGMXBKPGFP-KIUAEZIZSA-M

Cabotegravir, sold under the brand name Vocabria among others, is a antiretroviral medication used for the treatment of HIV/AIDS. It is available in the form of tablets and as an intramuscular injection, as well as in an injectable combination with rilpivirine under the brand name Cabenuva. [7] [13]

Contents

It is an integrase inhibitor with a carbamoyl pyridone structure similar to that of dolutegravir. [14]

In December 2021, the U.S. Food and Drug Administration approved cabotegravir for pre-exposure prophylaxis (PrEP) in at-risk people under the brand name Apretude. [15] In September 2023, it was approved for pre-exposure prophylaxis in the European Union. [11]

Medical uses

Cabotegravir in combination with rilpivirine is indicated for the treatment of human immunodeficiency virus type-1 (HIV-1) in adults. [1] [6] The combination injection is intended for maintenance treatment of adults who have undetectable HIV levels in the blood (viral load less than 50 copies/mL) with their current antiretroviral treatment, and when the virus has not developed resistance to non-nucleoside reverse transcriptase inhibitors (NNRTIs) and integrase strand transfer inhibitors. [6] The tablets are used to check whether a person tolerates the treatment before the injection therapy is started. [16] [6]

The two medicines are the first antiretroviral drugs that come in a long-acting injectable formulation. [16]

Cabotegravir (Apretude) is indicated for use in at-risk people weighing at least 35 kilograms (77 lb) for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV. [15]

Contraindications and interactions

Cabotegravir must not be combined with the drugs rifampicin, rifapentine, carbamazepine, oxcarbazepine, phenytoin or phenobarbital, which induce the enzyme UGT1A1. [6] These drugs significantly decrease cabotegravir concentrations in the body and thus may reduce its effectiveness. [13] [6] Additionally, they induce the enzyme CYP3A4, which leads to reduced rilpivirine concentrations in the body. [6] [17] [18] [19]

Adverse effects

The most common side effects of the injectable combination therapy with rilpivirine are reactions at the injection site (in up to 84% of patients) such as pain and swelling, as well as headache (up to 12%) and fever or feeling hot (in 10%). For the tablets, headache and a hot feeling were slightly less frequent. Less common side effects (under 10%) for both formulations are depressive disorders, insomnia, and rashes. [13]

Pharmacology

Mechanism of action

Cabotegravir is an integrase strand transfer inhibitor. This means it blocks the HIV's enzyme integrase, thereby preventing its genome from being integrated into the human cells' DNA. [13] As this is a necessary step for the virus to replicate, its further spread is hampered. [13]

Pharmacokinetics

Cabotegravir glucuronide, the main metabolite in human bile and urine Cabotegravir glucuronide.svg
Cabotegravir glucuronide, the main metabolite in human bile and urine

When taken by mouth, cabotegravir reaches highest blood plasma levels after three hours. Taking the drug together with food slightly increases its concentrations in the blood, but this is not clinically relevant. After injection into the muscle, cabotegravir is slowly absorbed into the bloodstream, reaching its highest blood plasma levels after about seven days. [13]

Over 99% of the substance are bound to plasma proteins. The drug is inactivated in the body by glucuronidation, mainly by the enzyme UGT1A1, and to a much lesser extent by UGT1A9. More than 90% of the circulating substance are the unchanged cabotegravir, however. The biological half-life is 41 hours for the tablets and 5.6 to 11.5 weeks for the injection. [13]

Elimination has only been studied for oral administration: Most of the drug is eliminated via the faeces in unchanged form (47%). It is not known how much of this amount comes from the bile, and how much was not absorbed in the first place. (The bile actually contains the glucuronide, but this could be broken up again in the gut lumen to give the parent substance that is observed in the faeces.) To a lesser extent it is excreted via the urine (27%), almost exclusively as the glucuronide. [13]

Pharmacogenomics

UGT1A1 poor metabolizers have 1.3- to 1.5-fold increased cabotegravir concentrations in the body. This is not considered clinically significant. [13]

Chemistry

Cabotegravir is a white to off-white, crystalline powder that is practically insoluble in aqueous solutions under pH 9, and slightly soluble above pH 10. It is slightly acidic with a pKa of 7.8 for the enolic acid and 11.1 (calculated) for the carboxamide. The molecule has two asymmetric carbon atoms; only one of the four possible configurations is present in the medication. [21]

Formulation

In studies, the agent was packaged into nanoparticles (GSK744LAP) conferring a biological half-life of 21 to 50 days[ citation needed ] following a single dose. The marketed injection achieves its long half-life not via nanoparticles but with a suspension of the free cabotegravir acid. The tablets contain cabotegravir sodium salt. [21]

History

Cabotegravir was examined in the clinical trials HPTN 083 and HPTN 084. [22] [23]

Society and culture

In 2020, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Vocabria intended for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in combination with rilpivirine injection. [24] The EMA also recommended marketing authorization be given for rilpivirine and cabotegravir injections to be used together for the treatment of people with HIV-1 infection. [16] Cabotegravir was approved for medical use in the European Union in December 2020. [9]

In December 2021, the U.S. Food and Drug Administration (FDA) approved cabotegravir for pre-exposure prophylaxis. [15] The FDA granted the approval of Apretude to Viiv. [15]

Zimbabwe became the first African country to approve the drug in October 2022. [25]

Names

Cabotegravir is the United States Adopted Name (USAN) [26] and the international nonproprietary name (INN). [27]

Research

Pre-exposure prophylaxis

In 2020, results for some studies were released showing success in using injectable cabotegravir for long-acting pre-exposure prophylaxis (PrEP) with greater efficacy than the emtricitabine/tenofovir combination being widely used for PrEP at the time. [28] [29]

The safety and efficacy of cabotegravir to reduce the risk of acquiring HIV were evaluated in two randomized, double-blind trials that compared cabotegravir to emtricitabine/tenofovir, a once daily oral medication for HIV PrEP. [15] Trial 1 included HIV-uninfected men and transgender women who have sex with men and have high-risk behavior for HIV infection. [15] Trial 2 included uninfected cisgender women at risk of acquiring HIV. [15]

In Trial 1, 4,566 cisgender men and transgender women who have sex with men received either cabotegravir or emtricitabine/tenofovir. [15] The trial measured the rate of HIV infections among trial participants taking daily cabotegravir followed by cabotegravir injections every two months compared to daily oral emtricitabine/tenofovir. [15] The trial showed participants who took cabotegravir had 69% less risk of getting infected with HIV when compared to participants who took emtricitabine/tenofovir. [15]

In Trial 2, 3,224 cisgender women received either cabotegravir or emtricitabine/tenofovir. [15] The trial measured the rate of HIV infections in participants who took oral cabotegravir and injections of cabotegravir compared to those who took emtricitabine/tenofovir orally. [15] The trial showed participants who took cabotegravir had 90% less risk of getting infected with HIV when compared to participants who took emtricitabine/tenofovir. [15]

Related Research Articles

<span class="mw-page-title-main">Emtricitabine</span> Antiretroviral drug used to treat HIV infection

Emtricitabine, with trade name Emtriva, is a nucleoside reverse-transcriptase inhibitor (NRTI) for the prevention and treatment of HIV infection in adults and children. In 2019, it was the 494th most commonly prescribed medication in the United States, with more than 3 thousand prescriptions.

<span class="mw-page-title-main">Tenofovir disoproxil</span> Antiviral drug used to treat or prevent HIV and hepatitis infections

Tenofovir disoproxil, sold under the trade name Viread among others, is a medication used to treat chronic hepatitis B and to prevent and treat HIV/AIDS. It is generally recommended for use with other antiretrovirals. It may be used for prevention of HIV/AIDS among those at high risk before exposure, and after a needlestick injury or other potential exposure. It is sold both by itself and together in combinations such as emtricitabine/tenofovir, efavirenz/emtricitabine/tenofovir, and elvitegravir/cobicistat/emtricitabine/tenofovir. It does not cure HIV/AIDS or hepatitis B. It is available by mouth as a tablet or powder.

<span class="mw-page-title-main">Efavirenz</span> Antiretroviral medication

Efavirenz (EFV), sold under the brand names Sustiva among others, is an antiretroviral medication used to treat and prevent HIV/AIDS. It is generally recommended for use with other antiretrovirals. It may be used for prevention after a needlestick injury or other potential exposure. It is sold both by itself and in combination as efavirenz/emtricitabine/tenofovir. It is taken by mouth.

<span class="mw-page-title-main">Emtricitabine/tenofovir</span> Drug combination for HIV/AIDS prophylaxis and treatment

Emtricitabine/tenofovir, sold under the brand name Truvada among others, is a fixed-dose combination antiretroviral medication used to treat and prevent HIV/AIDS. It contains the antiretroviral medications emtricitabine and tenofovir disoproxil. For treatment, it must be used in combination with other antiretroviral medications. For prevention before exposure, in those who are at high risk, it is recommended along with safer sex practices. It does not cure HIV/AIDS. Emtricitabine/tenofovir is taken by mouth.

<span class="mw-page-title-main">Pre-exposure prophylaxis for HIV prevention</span> HIV prevention strategy using preventative medication for HIV-negative individuals

Pre-exposure prophylaxis for HIV prevention, commonly known as PrEP, is a form of pre-exposure prophylaxis to prevent HIV infection, the cause of HIV/AIDS.

<span class="mw-page-title-main">Efavirenz/emtricitabine/tenofovir</span> Combination drug for HIV

Efavirenz/emtricitabine/tenofovir, sold under the brand name Atripla among others, is a fixed-dose combination antiretroviral medication used to treat HIV/AIDS. It contains efavirenz, emtricitabine, and tenofovir disoproxil. It can be used by itself or together with other antiretroviral medications. It is taken by mouth.

<span class="mw-page-title-main">HIV Prevention Trials Network</span>

The HIV Prevention Trials Network (HPTN) is a worldwide collaborative clinical trials network that brings together investigators, ethicists, community and other partners to develop and test the safety and efficacy of interventions designed to prevent the acquisition and transmission of HIV. HPTN studies evaluate new HIV prevention interventions and strategies in populations and geographical regions that bear a disproportionate burden of infection. The HPTN is committed to the highest ethical standards for its clinical trials and recognizes the importance of community engagement in all phases of the research process.

Integrase inhibitors (INIs) are a class of antiretroviral drug designed to block the action of integrase, a viral enzyme that inserts the viral genome into the DNA of the host cell. Since integration is a vital step in retroviral replication, blocking it can halt further spread of the virus. Integrase inhibitors were initially developed for the treatment of HIV infection, but have been applied to other retroviruses. The class of integrase inhibitors called integrase strand transfer inhibitors (INSTIs) are in established medical use. Other classes, such as integrase binding inhibitors (INBIs), are still experimental.

<span class="mw-page-title-main">Rilpivirine</span> HIV treatment

Rilpivirine, sold under the brand names Edurant and Rekambys, is a medication, developed by Tibotec, used for the treatment of HIV/AIDS. It is a second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) with higher potency, longer half-life and reduced side-effect profile compared with older NNRTIs such as efavirenz.

iPrEx

iPrEx was a phase III clinical trial to determine whether the antiretroviral medication emtricitabine/tenofovir could safely and effectively prevent HIV acquisition through sex in men who have sex with men and transgender women. iPrEx was the first human study of an HIV prevention strategy known as pre-exposure prophylaxis, or PrEP.

<span class="mw-page-title-main">Dolutegravir</span> Chemical compound

Dolutegravir (DTG), sold under the brand name Tivicay, is an antiretroviral medication used, together with other medication, to treat HIV/AIDS. It may also be used, as part of post exposure prophylaxis, to prevent HIV infection following potential exposure. It is taken by mouth.

Emtricitabine/rilpivirine/tenofovir is a fixed-dose combination of antiretroviral drugs for the treatment of HIV/AIDS. The drug was co-developed by Gilead Sciences and Johnson & Johnson's Tibotec division and was approved by the Food and Drug Administration in August 2011, and by the European Medicines Agency in November 2011, for patients who have not previously been treated for HIV. It is available as a once-a-day single tablet.

<span class="mw-page-title-main">Tenofovir alafenamide</span> Chemical compound

Tenofovir alafenamide, sold under the brand name Vemlidy, is an antiviral medication used against hepatitis B and HIV. It is used for the treatment of chronic hepatitis B virus (HBV) infection in adults with compensated liver disease and is given in combination with other medications for the prevention and treatment of HIV. It is taken by mouth.

Elvitegravir/cobicistat/emtricitabine/tenofovir, sold under the brand name Stribild, also known as the Quadpill, is a fixed-dose combination antiretroviral medication for the treatment of HIV/AIDS. Elvitegravir, emtricitabine and tenofovir disoproxil directly suppress viral reproduction. Cobicistat increases the effectiveness of the combination by inhibiting the liver and gut wall enzymes that metabolize elvitegravir. It is taken by mouth.

<span class="mw-page-title-main">Abacavir/dolutegravir/lamivudine</span> Drug combination for HIV

Abacavir/dolutegravir/lamivudine, sold under the brand name Triumeq among others, is a fixed-dose combination antiretroviral medication for the treatment of HIV/AIDS. It is a combination of three medications with different and complementary mechanisms of action: abacavir, dolutegravir and lamivudine.

HPTN 083 is a 2016 clinical trial which compares cabotegravir injections with oral use of Emtricitabine/tenofovir as pre-exposure prophylaxis ("PrEP") for prevention of HIV/AIDS.

<span class="mw-page-title-main">Bictegravir/emtricitabine/tenofovir alafenamide</span> Fixed dose combination HIV drug

Bictegravir/emtricitabine/tenofovir alafenamide, sold under the brand name Biktarvy, is a fixed-dose combination antiretroviral medication for the treatment of HIV/AIDS. One tablet, taken orally once daily, contains 50 mg bictegravir, 200 mg emtricitabine, and 25 mg tenofovir alafenamide. It was approved for use in the United States in February 2018, and for use in the European Union in June 2018.

Dolutegravir/lamivudine, sold under the brand name Dovato, is a fixed-dose combination antiretroviral medication for the treatment of HIV/AIDS. It contains dolutegravir, as the salt, an integrase strand transfer inhibitor (INSTI), and lamivudine, a nucleoside analogue reverse transcriptase inhibitor (NRTI). It is taken by mouth.

<span class="mw-page-title-main">Cabotegravir/rilpivirine</span> Co-packaged antiretroviral medication

Cabotegravir/rilpivirine, sold under the brand name Cabenuva, is a co-packaged antiretroviral medication for the treatment of HIV/AIDS. It contains cabotegravir and rilpivirine in a package with two separate injection vials.

<span class="mw-page-title-main">Lenacapavir</span> Antiretroviral medication

Lenacapavir, sold under the brand name Sunlenca, is an antiretroviral medication used to treat HIV/AIDS. It is taken by mouth or by subcutaneous injection.

References

  1. 1 2 3 "Vocabria (cabotegravir) film-coated tablets Product Information". TGA eBS. 12 June 2021. Archived from the original on 13 June 2021. Retrieved 12 June 2021.
  2. 1 2 "Vocabria". Therapeutic Goods Administration (TGA). 26 February 2021. Archived from the original on 9 September 2021. Retrieved 8 September 2021.
  3. ↑ "Summary for ARTG Entry: 323721 VOCABRIA cabotegravir (as sodium) 30 mg film-coated tablet, bottle". Therapeutic Goods Administration. The Government of Australia. 13 August 2021.[ permanent dead link ]
  4. ↑ "Vocabria Product information". Health Canada. 25 April 2012. Archived from the original on 24 February 2021. Retrieved 22 January 2021.
  5. ↑ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA . Retrieved 22 October 2023.
  6. 1 2 3 4 5 6 7 "Vocabria- cabotegravir sodium tablet, film coated". DailyMed. Archived from the original on 15 June 2021. Retrieved 12 June 2021.
  7. 1 2 "FDA Approves First Extended-Release, Injectable Drug Regimen for Adults Living with HIV". U.S. Food and Drug Administration (FDA) (Press release). 21 January 2021. Archived from the original on 21 January 2021. Retrieved 21 January 2021.PD-icon.svg This article incorporates text from this source, which is in the public domain .
  8. ↑ "Apretude- cabotegravir kit". DailyMed. Archived from the original on 25 December 2021. Retrieved 24 December 2021.
  9. 1 2 "Vocabria EPAR". European Medicines Agency (EMA). 13 October 2020. Archived from the original on 14 July 2021. Retrieved 22 January 2021. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  10. ↑ "Vocabria Product information". Union Register of medicinal products. Archived from the original on 5 March 2023. Retrieved 3 March 2023.
  11. 1 2 "Apretude EPAR". European Medicines Agency. 20 September 2023. Archived from the original on 6 October 2023. Retrieved 20 September 2023.
  12. ↑ "Apretude Product information". Union Register of medicinal products. 20 September 2023. Archived from the original on 6 October 2023. Retrieved 1 October 2023.
  13. 1 2 3 4 5 6 7 8 9 "Vocabria: EPAR – Product information" (PDF). European Medicines Agency. 5 January 2021. Archived (PDF) from the original on 10 April 2021. Retrieved 23 February 2021.
  14. ↑ Borrell B (March 2014). "Long-acting shot prevents infection with HIV analogue". Nature News. doi:10.1038/nature.2014.14819. S2CID   184399045.
  15. 1 2 3 4 5 6 7 8 9 10 11 12 13 "FDA Approves First Injectable Treatment for HIV Pre-Exposure Prevention". U.S. Food and Drug Administration (FDA) (Press release). 20 December 2021. Archived from the original on 22 April 2022. Retrieved 21 December 2021.PD-icon.svg This article incorporates text from this source, which is in the public domain .
  16. 1 2 3 "First long-acting injectable antiretroviral therapy for HIV recommended approval" (Press release). European Medicines Agency (EMA). 16 October 2020. Archived from the original on 17 October 2020. Retrieved 16 October 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  17. ↑ "Cabenuva- cabotegravir and rilpivirine kit". DailyMed. Archived from the original on 15 June 2021. Retrieved 12 June 2021.
  18. ↑ "Edurant- rilpivirine hydrochloride tablet, film coated". DailyMed. Archived from the original on 28 October 2020. Retrieved 12 June 2021.
  19. ↑ "Rilpivirine Monograph for Professionals". Drugs.com. 24 September 2020. Archived from the original on 10 April 2021. Retrieved 12 June 2021.
  20. ↑ Patel M, Eberl HC, Wolf A, Pierre E, Polli JW, Zamek-Gliszczynski MJ (August 2019). "Mechanistic Basis of Cabotegravir-Glucuronide Disposition in Humans". The Journal of Pharmacology and Experimental Therapeutics. 370 (2): 269–277. doi: 10.1124/jpet.119.258384 . PMID   31175220. S2CID   182950312.
  21. 1 2 "Vocabria: EPAR – Public assessment report" (PDF). European Medicines Agency. 5 January 2021. Archived (PDF) from the original on 10 April 2021. Retrieved 24 February 2021.
  22. ↑ "HPTN083 — Prevention Now". HIV Prevention Trials Network. Archived from the original on 27 July 2018. Retrieved 2 December 2017.
  23. ↑ "HPTN084 — Prevention Now". HIV Prevention Trials Network. Archived from the original on 27 July 2018. Retrieved 2 December 2017.
  24. ↑ "Vocabria: Pending EC decision". European Medicines Agency (EMA). 16 October 2020. Archived from the original on 1 January 2021. Retrieved 16 October 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  25. ↑ Chingono N (20 October 2022). "Zimbabwe becomes first African nation to approve HIV prevention drug". The Guardian. Archived from the original on 7 February 2023. Retrieved 21 October 2022.
  26. ↑ "Adopted USANs" (PDF). American Medical Association. Retrieved 19 September 2014.
  27. ↑ World Health Organization (2015). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 73". WHO Drug Information. 29 (1): 70–1. hdl: 10665/331088 .
  28. ↑ Ryan G (7 July 2020). "Injectable PrEP Is Even More Effective Than Daily Truvada". Poz . Archived from the original on 13 June 2021. Retrieved 9 November 2020.
  29. ↑ Ryan G (9 November 2020). "For Women, Injectable Cabotegravir Is More Effective Than Truvada as PrEP". Poz . Archived from the original on 8 May 2021. Retrieved 9 November 2020.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.